Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Ph 1 study for R/R Follicular Lymphoma
“R/R FL is a disease that repeatedly recurs and is difficult to cure, and new treatment strategies are required. We are very pleased that bispecific antibody mosunetuzumab achieved CRR and showed promising results for remission. We will continue efforts to apply for the approval of mosunetuzumab in Japan to deliver this drug as a new treatment option for patients as quickly as possible,” said Dr. Osamu Okuda, Chugai’s President and CEO.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.